Inactive Instrument
Incannex Healthcare Stock Australian S.E.
Stocks
IHL
AU000000IHL8
Biotechnology & Medical Research
OTC Markets Traded
| Market Cap | 55.47M 38.36M 33.7M 31.04M 29.03M 54.5M 3.63B 374M 144M 1.78B 144M 141M 6.2B | P/E 2026 * |
-2.08x | P/E 2027 * | -2.25x |
|---|---|---|---|---|---|
| Enterprise Value | 55.47M 38.36M 33.7M 31.04M 29.03M 54.5M 3.63B 374M 144M 1.78B 144M 141M 6.2B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | - |
| Free-Float |
87.66% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | -10.87% |
| Manager | Title | Age | Since |
|---|---|---|---|
Joel Latham
CEO | Chief Executive Officer | 37 | 01/01/2016 |
Joseph Swan
DFI | Director of Finance/CFO | 35 | 29/02/2024 |
Parisa Asvadi
CTO | Chief Tech/Sci/R&D Officer | - | 01/01/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
Robert Clark
BRD | Director/Board Member | 66 | 01/11/2023 |
| Director/Board Member | 62 | 01/11/2023 | |
Troy Valentine
CHM | Chairman | 52 | 01/11/2023 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -10.87% | -31.67% | - | - | 38.88M | |
| +2.14% | +6.81% | +72.57% | +123.91% | 56.65B | |
| -0.49% | +6.98% | +62.88% | +67.95% | 47.49B | |
| +0.48% | -0.20% | -14.93% | -15.55% | 22.81B | |
| +3.60% | +4.81% | -0.52% | +402.21% | 21.37B | |
| +1.30% | +0.71% | +29.21% | -17.51% | 16.12B | |
| +3.20% | +7.18% | +24.07% | -34.39% | 15.56B | |
| -0.02% | -3.13% | +27.17% | +158.25% | 12.91B | |
| 0.00% | +15.02% | +133.24% | +273.89% | 12.86B | |
| +1.43% | -5.06% | +23.53% | - | 11.67B | |
| Average | -0.33% | +1.74% | +39.69% | +119.84% | 24.16B | |
| Weighted average by Cap. | +0.85% | +3.17% | +45.67% | +112.92% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | - |
| Net income | -24.91M -17.23M -15.14M -13.94M -13.04M -24.48M -1.63B -168M -64.77M -801M -64.68M -63.28M -2.78B | -24.89M -17.21M -15.12M -13.92M -13.03M -24.45M -1.63B -168M -64.7M -800M -64.61M -63.21M -2.78B |
| Net Debt | - | - |
Employees
12
